California rocket fuel
California rocket fuel is a nickname for taking two antidepressants together: mirtazapine (Remeron) with venlafaxine (Effexor), an SNRI. Prescribers sometimes use a combination like this when one antidepressant has not helped enough, but trials have not shown it works better than other options, and it adds side effects such as sleepiness and weight gain. It is a prescribing choice for a doctor to make, not a fixed recipe.
Also called: CRF, Mirtazapine and venlafaxine, Venlafaxine plus mirtazapine.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
Does California rocket fuel work?
The evidence is thin and mixed. The biggest test of this pair is CO-MED, a US trial of 665 outpatients published in 2011: venlafaxine with mirtazapine brought 37.7% of people to remission at 12 weeks, against 38.8% on escitalopram with a placebo, so no gain over one antidepressant. The mean number of worsening adverse events was higher on the pair, 5.7 against 4.7. Both medications started on day one there, as first-step treatment.
A 2010 double-blind trial of 105 people starting treatment for depression, published in the American Journal of Psychiatry, also gave both medications from treatment initiation: 58% of those on mirtazapine with venlafaxine were in remission at 6 weeks, against 25% of those on fluoxetine alone. The two other combinations in the same trial did about as well, 52% for mirtazapine with fluoxetine and 46% for mirtazapine with bupropion. It was small, ran 6 weeks and had no group taking mirtazapine on its own, and nobody in it was in the position most readers are in, already on one antidepressant and being offered a second.
A larger 2018 trial in the BMJ tested that position instead. It added mirtazapine for 480 adults in UK general practice who were still depressed after at least 6 weeks on an SSRI or SNRI. At 12 weeks their depression scores were 1.83 points lower on the Beck Depression Inventory than with a placebo added, and the authors found no evidence of a clinically important benefit. The trial covered SSRIs and SNRIs as a group, not venlafaxine on its own.
Is it safe to take mirtazapine and venlafaxine together?
The pair is not off limits. The Remeron label puts SSRIs and SNRIs in its drug interactions table with one instruction, to monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. In the 2018 trial, side effects were more common in the group given mirtazapine, and the people who had them were more likely to stop the added medication.
Both medications act on serotonin. The US labels for Remeron and for Effexor XR each warn that the drug can precipitate serotonin syndrome, which is potentially life-threatening, and that the risk is higher when it is combined with other serotonergic drugs. The signs both labels list include agitation, hallucinations, delirium, a fast or unstable heartbeat, dizziness, sweating, flushing, high temperature, tremor, rigidity, twitching, seizures, nausea, vomiting and diarrhea.
That needs emergency care: call 911 or your local emergency number, or ask someone with you to call.
Why would a doctor suggest California rocket fuel?
The two medications reach the same two chemical messengers from different directions. By its label, venlafaxine is thought to work by blocking the reuptake of serotonin and norepinephrine. Mirtazapine blocks receptors instead, and the Remeron label puts the effect of that as enhancing central noradrenergic and serotonergic activity. That is the reasoning for this pair rather than two medications doing the same job twice.
What mirtazapine brings with it is part of the choice. Sleepiness came with it for 54% of people in its own US trials, against 18% on placebo, and a bigger appetite for 17% against 2%. Depending on how you are sleeping and eating, that can count for you or against you. If you are sleepy during the day, say so early: in those trials somnolence was enough for 10.4% of people to stop mirtazapine, against 2.2% on placebo. Whether a combination suits you depends on your history, your other medicines and your health, so ask how and when it will be reviewed.
What to do
If a doctor suggests adding mirtazapine to venlafaxine, ask what result they expect, how long to give it, which side effects to watch for and when you would review it together. Tell them about every other medication and supplement you take. If you have thoughts of harming yourself, call or text 988 in the US, or your local emergency number.
Read the mirtazapine guide
How withClaro helps
- Log both doses and any side effects in one place
- Share a PDF report with your prescriber before your review
Get the withClaro app on the App Store
Related terms
Sources
- Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. American Journal of Psychiatry, 2010.
- Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J, Burns A, Chew-Graham CA, Anderson IM, Shepherd T, Campbell J, Dickens CM, Carter M, Jenkinson C, Macleod U, Gibson H, Davies S, Wiles NJ. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ, 2018.
- Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. American Journal of Psychiatry, 2011.
- U.S. Food and Drug Administration. Remeron and RemeronSolTab (mirtazapine): prescribing information. FDA / DailyMed, 2021.
- U.S. Food and Drug Administration. Effexor XR (venlafaxine extended-release capsules): prescribing information. FDA / DailyMed, 2025.
All glossary terms